Patent: 6,960,352
✉ Email this page to a colleague
Summary for Patent: 6,960,352
| Title: | Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent |
| Abstract: | The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent causing vessel occlusion. |
| Inventor(s): | Noujaim; Antoine (Edmonton, CA), Person; Roland H. (Kelowna, CA), Stewart; Michael W. (St Albert, CA) |
| Assignee: | ViRexx Medical Corporation (Edmonton, CA) |
| Application Number: | 10/241,717 |
| Patent Claims: | see list of patent claims |
Details for Patent 6,960,352
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Baxalta Us Inc. | VONVENDI | von willebrand factor (recombinant) | For Injection | 125577 | 12/08/2015 | ⤷ Try a Trial | 2021-09-12 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
